Event reminder - Pharma and Biotech Patent Litigation Summit

New acquisition:
Merpel and Girl with a Pearl Earring

As The IPKat reported a while ago, on 22-24 January 2024, the Pharma and Biotech Patent Litigation Summit will return to Amsterdam (Netherlands). A UPC Litigation Forum will take place on 22 January too.

This 3-day conference promises to offer 200+ private practice and in-house participants a forum of practical discussions surrounding the leading patent litigation topics in Europe, with a compare-and-contrast method with jurisdictions further afield.

According to the organizers, this internationally recognized summit will provide the necessary practical tools to defend patent litigation challenges for pharma and biotech products, whilst also maximizing litigation strategies to allow for successful IP protection. With the central case law and regulatory updates, this event focuses on the European market and those working within life science IP.

As the agenda also indicates, this year’s edition will focus on UPC litigation strategies, pharma and biotech patent litigation, patentability concerns. Speakers include judges from the UK, EPO, USA and the UPC.

The IPKat has negotiated a special discount for readers. By using IPKAT at checkout, a 10% discount in the registration fee will be applied. Click here for further details and to register.
Event reminder - Pharma and Biotech Patent Litigation Summit Event reminder - Pharma and Biotech Patent Litigation Summit Reviewed by Eleonora Rosati on Tuesday, November 21, 2023 Rating: 5

No comments:

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html

Powered by Blogger.